

PERSONAL INFORMATION

SURNAME Bertias
NAME George
e-mail gbertias@uoc.gr
PHONE NUMBER +2810 39 4635

CURRENT POSITION(S)

Associate Professor in Rheumatology-Clinical Immunology, Medical School, University of Crete (UoC), Greece
2021 - Affiliated Faculty and Group Leader, Laboratory of Rheumatology, Autoimmunity and Inflammation, Institute of Molecular Biology and Biotechnology (IMBB), Foundation for Research and Technology – Hellas (FORTH), Greece

PREVIOUS POSITION(S)

2020 – 2021 Associate Professor (tenured) in Rheumatology-Clinical Immunology, Medical School, UoC, Greece
2016 – 2020 Assistant Professor (tenure-track) in Rheumatology-Clinical Immunology, Medical School, UoC, Greece
2014 – 2016 Lecturer, in Rheumatology-Clinical Immunology, Medical School, UoC, Greece

EDUCATION

2014 – 2018 Fellowship in Rheumatology, University Hospital of Heraklion, Greece
2012 – 2014 Post-doctoral fellowship, Department of Basic Sciences, Medical School, UoC (Supervisor: Prof. Aristidis Eliopoulos)
2010 – 2011 Post-doctoral fellowship, Inflammatory Diseases Section, Genetics and Genomics Branch, National Institutes of Health (NIAMS, NHGRI), MD (Supervisor: Prof. Daniel Kastner)
2009 – 2010 Residency in Internal Medicine, University Hospital of Heraklion, Greece
2006 – 2009 Ph.D. in Immunology-Autoimmunity, Medical School, UoC, Greece, “*Cum Laude*”
2004 – 2006 Master’s degree (M.Sc.), Graduate Program “Molecular Basis of Human Disease”, Medical School, UoC, “*Cum Laude*”
2003 – 2004 Internship, General Hospital of Sitia, Greece
2002 – 2003 Short-term research scholarship, Diabetes & Endocrinology Unit, Department of Medicine, Boston University Medical Center (MA, USA) (Supervisor: Prof. Neil Ruderman)
1996 – 2002 Medical degree, Medical School, UoC, “*Cum Laude*”

MEMBERSHIPS & REVIEWING ACTIVITIES

• REVIEWING ACTIVITIES – COMMISSIONS OF TRUST

2014–Present Grants Reviewer & panel member: *California Institute for Regenerative Medicine’s (CIRM) Clinical Program; European Research Council (ERC) Starting Grants panel member (2022-204); Research Foundation – Flanders (FWO); UK Medical Research Council (MRC); Health Research Charities Ireland; Wellcome Trust Investigator Award in Science; Lupus Foundation of America; Icelandic Research Fund; Italian Foundation of Research on Arthritis; The Romanian National Authority for Scientific Research; US-Israel Binational Science Foundation; South African MRC; Greek Secretariat of Research and Technology; Cyprus Research Promotion Foundation; Italian Ministry for Education, University and Research*

MEMBERSHIPS & REVIEWING ACTIVITIES (continued)

• REVIEWING ACTIVITIES – COMMISSIONS OF TRUST

- 2011–Present Abstracts Reviewer panel member: Annual European Congress of Rheumatology (EULAR); European Lupus Meetings
- 2012–Present Ad hoc reviewer for >20 Journals including: *Annals of the Rheumatic Diseases* (IF 16.1), *Arthritis & Rheumatology* (IF 9.6); *BMC Medical Genomics* (IF 2.7); *Nature Reviews in Rheumatology* (IF 16.6); *New England Journal of Medicine*; *Scientific Reports* (IF: 4.0)
- 2016–Present Member of the Editorial Board: *Clinical Immunology, Rheumatic & Musculoskeletal Diseases (RMD) Open*, *Frontiers in Medicine*, *Lupus Science & Medicine*,
- 2019 Scientific Advisory Board, International Phase III clinical trial on secukinumab (anti-IL17A) in lupus nephritis (Novartis, CAIN457Q12301)
- 2019–Present Scientific Advisory Board, International multicentre study STEPS (“STERoid withdrawal in Patients with Systemic Lupus Erythematosus”)
- 2018–2021 Member of the International Steering Committee DORIS (Definition Of Remission in Systemic Lupus Erythematosus) (*coordinator*: Prof. R. Vollehoven, UMC, Netherlands)
- 2022–Present Data Monitoring Committee (DMC) member: CVAY736K12301 clinical program (NOVARITS)

• MEMBERSHIPS OF SCIENTIFIC SOCIETIES

- 2021–Present EULAR Congress Committee
- 2020–Present Executive Committee of the European Lupus Society SLEuro (<https://sleuro.org>)
- 2012–2018 EULAR (European League Against Rheumatism) and EMEUNET
- 2012–Present Greek Rheumatology Society
- 2002–Present Medical Society of Heraklion, Greece

TEACHING ACTIVITIES

- 2014–Present Course coordinator and tutor of the postgraduate course “*Biostatistics, Epidemiology and Clinical Methodology*”, Graduate Program “Molecular Basis of Human Disease” (University of Crete Medical School)
- 2014–Present Teaching the postgraduate class “Costimulatory receptors and immune regulation”
- 2014–Present Teaching the postgraduate classes “Innate and Adaptive Immunity”, “Immune regulation, autoimmunity and immunotherapy”, Schools of Medicine/Biology (UoC) and IMBB
- 2014–Present Undergraduate classes: “Basic Immunology”, “Pathophysiology”, “Internal Medicine”, School of Medicine (UoC)

SUPERVISION OF GRADUATE STUDENTS & POSTDOCTORAL FELLOWS

- 4 post-doctoral fellows and senior scientists
- 7 PhD students
- 8 Master’s students

FELLOWSHIPS and AWARDS

- 2013 Hellenic State Scholarships Foundation: Post-doctoral “Excellence” Scholarship
- 2010 Nominated (“A. Onassis” Foundation) as one of the 3 most promising young researchers in Greece – representation at the 60th Meeting of Nobel Laureates in Lindau, 2010
- 2006 “A. Onassis” Foundation scholarship (G-ZB 051/2005-2006) for postgraduate studies
- 2004 Graduate Program “Molecular basis of Human Disease” scholarship
- 2004 “M. Manasaki” Foundation scholarship for graduate studies
- 2002 Award (GlaxoSmithKline) for graduating 1st among 100 medical students (UoC)
- 1996–2000 Hellenic State Scholarships Foundation: 1st in the class in the Medical School (UoC)

• **ORGANISATION OF SCIENTIFIC MEETINGS**

- 2016–2020 **Co-organizer** of the 1st, 2nd and 3rd Lupus School (Athens, Greece)
2017 Scientific Committee, 26th Greek Rheumatology Meeting (Thessaloniki, Greece)
2016 Scientific Committee, 10th European Lupus Meeting (Venice, Italy)
2014 **Co-organizer** of the 9th European Lupus Meeting (Athens, Greece)

• **INSTITUTIONAL RESPONSIBILITIES**

- 2017–Present **Deputy Director**, Joint Graduate Program “Molecular Biology-Biotechnology”, Schools of Medicine/Biology (UoC) and IMBB-FORTH
2019–Present Member of the Curriculum Evaluation Committee, Medical School, UoC
2017–2019 Co-coordinator, Career & Alumni Committee, Medical School, UoC
2018 Member of the Faculty Committee, Medical School, UoC
2014–2015 Member of the Safety Committee, Medical School, UoC
2016–2018 Member of the Undergraduate Studies Committee, Medical School, UoC
2014–2018 Member of the Steering Committee, Graduate Program “Molecular Basis of Human Disease”, Medical School, UoC

SELECTED PUBLICATIONS

PubMed link: <https://pubmed.ncbi.nlm.nih.gov/?term=Bertsias+G%5BAuthor%5D&sort=date>

1. NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN- α production in patients with SLE. Georgakis S, Gkirtzimanaki K, Papadaki G, ..., **Bertsias G**. *JCI Insight*. 2021; 6(21): e147671 **
2. Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Panousis NI*, **Bertsias GK***, Ongen H, ..., Dermitzakis ET, Boumpas DT. *Ann Rheum Dis*. 2019; 78(8): 1079-1089 **
3. Extensive fragmentation and re-organization of transcription in Systemic Lupus Erythematosus. Ntasis VF, Panousis NI, ..., **Bertsias GK**, Nikolaou C. *Sci Rep*. 2020; 10(1):16648 **
4. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Kirino Y*, **Bertsias G***, Ishigatsubo Y, ..., Remmers EF, Kastner DL. *Nat Genet*. 2013; 45(2): 202-7
5. Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Adamichou C, Genitsaridi I, ..., **Bertsias GK**. *Ann Rheum Dis*. 2021; 80(6): 758-766
6. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study. Nikoloudaki M, Nikolopoulos D, Koutsoviti S, ..., **Bertsias G**. *Front Immunol*. 2023; 13:1074044.
7. Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs. Garantziotis P, Nikolakis D, Doumas S, ..., **Bertsias G**, Boumpas DT. *Front Immunol*. 2022; 13: 860726 **
8. Recommendations for Systemic Lupus Erythematosus: Balancing Evidence and Eminence to Facilitate the Medical Care of a Complex Disease. **Bertsias G**. *Rheum Dis Clin North Am*. 2022; 48(3):617-636
9. In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Adamichou C, Nikolopoulos D, ..., **Bertsias GK**. *Ann Rheum Dis*. 2020; 79(2): 232-241
10. IFN α Impairs Autophagic Degradation of mtDNA Promoting Autoreactivity of SLE Monocytes in a STING-Dependent Fashion. Gkirtzimanaki K, Kabrani E, Nikoleri D, ..., **Bertsias G**, Boumpas DT, Verginis P. *Cell Rep*. 2018; 25(4): 921-933.e5
11. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Gergianaki I, Fanouriakakis A, ..., **Bertsias GK**. *Ann Rheum Dis*. 2017; 76(12): 1992-2000

12. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, **Bertias GK**, Boumpas DT. *Ann Rheum Dis*. 2019; 78(6): 736-745
13. Micro-RNA analysis of renal biopsies in human lupus nephritis demonstrates up-regulated miR-422a driving reduction of kallikrein-related peptidase 4. Krasoudaki E, Banos A, Stagakis E, Loupasakis K, Drakos E, Sinatkas V, Zampoulaki A, Papagianni A, Iliopoulos D, Boumpas DT, **Bertias GK**. *Nephrol Dial Transplant*. 2016; 31(10): 1676-86
14. Performance of Anti-nuclear Antibodies for Classifying Systemic Lupus Erythematosus: a Systematic Literature Review and Meta-regression of Diagnostic Data. Leuchten N, Hoyer A, Brinks R, ..., **Bertias G**. *Arthritis Care Res (Hoboken)*. 2017. doi: 10.1002/acr.23292. [ahead of print]
15. Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus. Papadaki E, Fanouriakis A, ..., **Bertias G**, Simos P, Boumpas DT. *Ann Rheum Dis*. 2018; 77(3): 441-448